|

PLD Clinical Trials

5 actively recruiting trials across 3 locations

Also known as: Doxil®, Pegylated Liposomal Doxorubicin, Pegylated liposomal doxorubicin

Pipeline

Phase 1: 1Phase 2: 2Phase 2/3: 2

Top Sponsors

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1
  • Regeneron Pharmaceuticals1
  • Novita Pharmaceuticals, Inc.1
  • Daiichi Sankyo1
  • Ascentage Pharma Group Inc.1

Indications

  • Cancer5
  • Platinum-resistant Recurrent Ovarian Cancer1
  • Platinum-resistant Ovarian Cancer1
  • Solid Cancer1
  • Advanced Solid Tumor1

Other2 trials

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Phase 2

Birmingham, Alabama1 trial

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2

Anchorage, Alaska1 trial

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Alaska Women's Cancer Care

Phase 2/3

Phoenix, Arizona1 trial

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

HonorHealth Cancer Care

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.